DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,616 filers reported holding DANAHER CORPORATION in Q3 2020. The put-call ratio across all filers is 1.03 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,158,730 | +4.4% | 24,824 | +1.0% | 0.11% | +11.8% |
| Q2 2023 | $5,897,465 | +103.8% | 24,573 | +114.0% | 0.10% | +72.9% |
| Q1 2023 | $2,893,939 | +41.9% | 11,482 | +49.5% | 0.06% | +34.1% |
| Q4 2022 | $2,038,918 | +25.2% | 7,682 | +21.8% | 0.04% | +18.9% |
| Q3 2022 | $1,628,000 | +14.9% | 6,305 | +12.9% | 0.04% | +19.4% |
| Q2 2022 | $1,417,000 | +6.8% | 5,587 | +23.6% | 0.03% | +34.8% |
| Q1 2022 | $1,327,000 | -5.3% | 4,522 | +6.1% | 0.02% | -4.2% |
| Q4 2021 | $1,402,000 | +8.1% | 4,262 | +0.0% | 0.02% | 0.0% |
| Q3 2021 | $1,297,000 | +14.8% | 4,260 | +1.2% | 0.02% | +20.0% |
| Q2 2021 | $1,130,000 | +20.5% | 4,209 | +1.0% | 0.02% | +11.1% |
| Q1 2021 | $938,000 | +1.3% | 4,167 | 0.0% | 0.02% | -5.3% |
| Q4 2020 | $926,000 | +11.6% | 4,167 | +8.1% | 0.02% | -5.0% |
| Q3 2020 | $830,000 | +206.3% | 3,854 | +151.9% | 0.02% | +185.7% |
| Q2 2020 | $271,000 | +28.4% | 1,530 | +0.5% | 0.01% | +16.7% |
| Q1 2020 | $211,000 | -88.4% | 1,523 | -87.1% | 0.01% | -85.0% |
| Q4 2019 | $1,812,000 | – | 11,803 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |